Skip to content

Clinical application and efficacy evaluation of TCM health management in patients with colorectal cancer after operation

Clinical application and efficacy evaluation of TCM health management in patients with colorectal cancer after operation

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085823
Enrollment
Unknown
Registered
2024-06-19
Start date
2024-06-30
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor

Interventions

Control:The control group received conventional treatment such as radiotherapy, chemotherapy, targeted therapy, immunotherapy, symptomatic treatment, etc. T
Observation group:The observation group received traditional Chinese medicine health management on the basis of the control group, and the management time was 2 years. The oral administration of tradi

Sponsors

Zibo Hospital of Integrated Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Postoperative patients with definite pathological diagnosis of colorectal cancer; (2) The Cartesian score is above 60 points; (3) Aged between 18 and 80; (4) The expected survival period is greater than 3 months; (5) The subject agrees and signs the informed consent

Exclusion criteria

Exclusion criteria: (1) Previous or combined history of other malignant tumors; (2) Those who have acute organ failure or other conditions requiring rescue and are not expected to receive TCM treatment; (3) The patient has developed intestinal obstruction and cannot take drugs, and needs intravenous high-energy nutrition; Have malabsorption syndrome or other diseases that affect gastrointestinal absorption, or have active peptic ulcer disease; (4) The expected survival is less than 3 months.

Design outcomes

Primary

MeasureTime frame
Disease-free survival;Progression free survival;Total survival period;

Secondary

MeasureTime frame
life quality score;TCM syndrome integral;Classification of toxic and side effects;tumor marker;

Countries

China

Contacts

Public ContactWanglei

Zibo Hospital of Integrated Chinese and Western Medicine

wangleizxyjh@163.com+86 151 6957 2822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026